Ligand Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:LGDN Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
09 May 25	Buy€138,545	Octavio Espinoza	Individual	1,500	€92.67
09 May 25	Buy€888,005	Todd Davis	Individual	9,510	€93.79
04 Mar 25	Sell€546,161	Octavio Espinoza	Individual	5,000	€109.23
23 Dec 24	Sell€235,497	Octavio Espinoza	Individual	2,104	€111.93
20 Sep 24	Sell€120,847	Matthew Korenberg	Individual	1,293	€93.46
20 Sep 24	Sell€118,975	Octavio Espinoza	Individual	1,275	€93.35
26 Aug 24	Sell€1,778,839	Matthew Korenberg	Individual	18,858	€95.21
09 Aug 24	Sell€1,644,915	Matthew Korenberg	Individual	18,245	€90.16
08 Aug 24	Buy€223,174	Todd Davis	Individual	2,500	€89.27

Insider Trading Volume

Insider Buying: LGDN insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LGDN?
Owner Type	Number of Shares	Ownership Percentage
State or Government	3,960	0.0201%
Individual Insiders	412,359	2.1%
Institutions	19,237,759	97.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 75% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15.1%	BlackRock, Inc.	2,920,235	€273.8m	-0.88%	no data
10.7%	The Vanguard Group, Inc.	2,055,732	€192.7m	-1.43%	no data
5.33%	Janus Henderson Group plc	1,027,549	€96.3m	1.23%	0.04%
4.7%	Macquarie Investment Management Business Trust	906,227	€85.0m	2.47%	0.12%
3.86%	Dimensional Fund Advisors LP	744,930	€69.8m	3.03%	0.01%
3.77%	State Street Global Advisors, Inc.	727,125	€68.2m	-2.22%	no data
3.33%	Congress Asset Management Company, LLP	642,712	€60.3m	3.42%	0.47%
3.15%	Stephens Investment Management Group, LLC	607,222	€56.9m	-0.91%	0.85%
2.87%	Chicago Capital, LLC	554,517	€52.0m	0.53%	1.53%
2.41%	Geode Capital Management, LLC	464,452	€43.5m	5.93%	no data
2.18%	Loomis Sayles & Company, L.P.	420,834	€39.5m	5.82%	0.06%
1.54%	Ashford Capital Management Inc	298,035	€27.9m	-4.07%	3.83%
1.54%	Rice Hall James & Associates, LLC	297,221	€27.9m	-2.53%	1.77%
1.52%	Northern Trust Global Investments	293,808	€27.5m	3.83%	no data
1.52%	DWS Investment Management Americas, Inc.	293,133	€27.5m	6.99%	0.13%
1.5%	St. Denis J. Villere & Co., LLC	288,827	€27.1m	0.62%	3.03%
1.49%	Deutsche Asset & Wealth Management	287,965	€27.0m	-0.38%	0.01%
1.45%	Impax Asset Management Group Plc	280,208	€26.3m	0%	0.1%
1.44%	Massachusetts Financial Services Company	277,791	€26.0m	0.38%	0.01%
1.12%	Aberdeen Group Plc	216,241	€20.3m	22.3%	0.01%
0.99%	Ranger Investment Management, L.P.	190,090	€17.8m	131%	1.37%
0.96%	Franklin Resources, Inc.	185,915	€17.4m	0.51%	0.01%
0.88%	Charles Schwab Investment Management, Inc.	168,874	€15.8m	-0.91%	no data
0.84%	Driehaus Capital Management LLC	162,170	€15.2m	-0.37%	0.1%
0.82%	Invesco Capital Management LLC	157,905	€14.8m	-13%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 04:30
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ligand Pharmaceuticals Incorporated is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Robert Wasserman	Benchmark Company
Gene Mack	Brean Capital